These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
411 related articles for article (PubMed ID: 33947675)
1. Paraspinal radiation recall myositis after gemcitabine for pancreatic adenocarcinoma. Barrios-Anderson A; Radhakrishnan R; Yu E; Shimanovsky A BMJ Case Rep; 2021 May; 14(5):. PubMed ID: 33947675 [TBL] [Abstract][Full Text] [Related]
2. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V; Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442 [TBL] [Abstract][Full Text] [Related]
3. Gemcitabine induced myositis in patients with pancreatic cancer: case reports and topic review. Pentsova E; Liu A; Rosenblum M; O'Reilly E; Chen X; Hormigo A J Neurooncol; 2012 Jan; 106(1):15-21. PubMed ID: 21811892 [TBL] [Abstract][Full Text] [Related]
4. Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial. Bachet JB; Hammel P; Desramé J; Meurisse A; Chibaudel B; André T; Debourdeau P; Dauba J; Lecomte T; Seitz JF; Tournigand C; Aparicio T; Meyer VG; Taieb J; Volet J; Monier A; Bonnetain F; Louvet C Lancet Gastroenterol Hepatol; 2017 May; 2(5):337-346. PubMed ID: 28397697 [TBL] [Abstract][Full Text] [Related]
5. Congestive heart failure secondary to gemcitabine nab-paclitaxel in patients with pancreatic cancer. John P; Butler H; Saif MW Anticancer Res; 2014 Dec; 34(12):7267-70. PubMed ID: 25503159 [TBL] [Abstract][Full Text] [Related]
6. [Nab-paclitaxel use in pancreatic cancer: practical aspects and consequences in a French oncology day-care unit]. Hubault M; Faure R; Walter T; Forestier J; Lombard-Bohas C; Pivot C Bull Cancer; 2015 May; 102(5):403-4. PubMed ID: 25866372 [No Abstract] [Full Text] [Related]
7. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. Von Hoff DD; Ervin T; Arena FP; Chiorean EG; Infante J; Moore M; Seay T; Tjulandin SA; Ma WW; Saleh MN; Harris M; Reni M; Dowden S; Laheru D; Bahary N; Ramanathan RK; Tabernero J; Hidalgo M; Goldstein D; Van Cutsem E; Wei X; Iglesias J; Renschler MF N Engl J Med; 2013 Oct; 369(18):1691-703. PubMed ID: 24131140 [TBL] [Abstract][Full Text] [Related]
8. Korn RL; Von Hoff DD; Borad MJ; Renschler MF; McGovern D; Curtis Bay R; Ramanathan RK Cancer Imaging; 2017 Aug; 17(1):23. PubMed ID: 28774338 [TBL] [Abstract][Full Text] [Related]
9. Treatment Outcome of Nab-paclitaxel Plus Gemcitabine for Leptomeningeal Carcinomatosis from Pancreatic Ductal Adenocarcinoma: An Autopsy Case Report. Iwatsuka K; Kikuta D; Shibuya H; Ogawa M; Gotoda T; Moriyama M; Nakagawara H; Hemmi A; Yamao K Intern Med; 2021 Dec; 60(23):3743-3748. PubMed ID: 34148945 [TBL] [Abstract][Full Text] [Related]
11. Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer. Borazanci E; Von Hoff DD Expert Rev Gastroenterol Hepatol; 2014 Sep; 8(7):739-47. PubMed ID: 24882381 [TBL] [Abstract][Full Text] [Related]
12. Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatment. Petrillo A; Pappalardo A; Pompella L; Tirino G; Calabrese F; Laterza MM; Caterino M; Ventriglia A; Orditura M; Conzo G; Molino C; Ciardiello F; Biglietto M; De Vita F Med Oncol; 2019 Aug; 36(10):83. PubMed ID: 31444639 [TBL] [Abstract][Full Text] [Related]
13. Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study. Zong Y; Yuan J; Peng Z; Lu M; Wang X; Shen L; Zhou J J Cancer Res Clin Oncol; 2021 May; 147(5):1529-1536. PubMed ID: 33191450 [TBL] [Abstract][Full Text] [Related]
14. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. Perri G; Prakash L; Qiao W; Varadhachary GR; Wolff R; Fogelman D; Overman M; Pant S; Javle M; Koay EJ; Herman J; Kim M; Ikoma N; Tzeng CW; Lee JE; Katz MHG JAMA Surg; 2020 Sep; 155(9):832-839. PubMed ID: 32667641 [TBL] [Abstract][Full Text] [Related]
15. Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma. Weiss GJ; Blaydorn L; Beck J; Bornemann-Kolatzki K; Urnovitz H; Schütz E; Khemka V Invest New Drugs; 2018 Feb; 36(1):96-102. PubMed ID: 29119276 [TBL] [Abstract][Full Text] [Related]